Brief: Icosavax Starts Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
09/09/2021 13:55
Sept 9 (Reuters) - Icosavax Inc ICVX.O :
* ICOSAVAX INITIATES PHASE 1/1B TRIAL OF VLP VACCINE
CANDIDATE
AGAINST RESPIRATORY SYNCYTIAL VIRUS
Source text for Eikon: ID:nGNX1S6yzl
Further company coverage: ICVX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Icosavax
See all newsU.S. RESEARCH ROUNDUP- Adobe, Costco Wholesale, Synopsys
Press Digest: British Business - Dec. 13
Brief: Icosavax Required To Pay Astrazeneca Finance And Holdings Termination Fee Of $27.2 Mln
Deals of the day-Mergers and acquisitions
France, Germany shares hit record highs, but give up gains after U.S CPI (updated)